Cara Therapeutics Captures $15M
Cara Therapeutics, a Shelton, CT-based developer of treatments for pain and inflammation, has raised $15 million in a Series D funding round, according to a press release posted online today. Rho Ventures led the round, which included previous backers Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi International, and MVM Life Science Partners. Cara has now raised more than $43 million from investors. The latest round will fund mid-stage development of the firm’s lead drug, CR845, for treating pain after surgeries.